Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GALT | US
0.13
4.80%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
19/09/2024
2.84
2.77
2.87
2.74
Galectin Therapeutics Inc. a clinical stage biopharmaceutical company engages in the research and development of therapies for fibrotic cancer and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis as well as for the treatment of cancer. The company through its Galectin Sciences LLC which is a collaborative joint venture co-owned by SBH Sciences Inc. to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross Georgia.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
63.1%1 month
70.6%3 months
70.9%6 months
81.5%-
-
207.70
-1.14
3.38
-4.04
-
-
-
176.87M
176.87M
-
-
-
-
-3.73K
42.10
16.88
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.58
Range1M
0.73
Range3M
1.00
Rel. volume
0.72
Price X volume
263.18K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LFCR | LFCR | Drug Manufacturers-Specialty & Generic | 5.62 | 173.65M | 8.08% | 20.72 | 241.85% |
CRDL | CRDL | Drug Manufacturers-Specialty & Generic | 2.25 | 157.36M | 2.27% | n/a | 1.07% |
Zomedica Pharmaceuticals Corp | ZOM | Drug Manufacturers-Specialty & Generic | 0.13 | 129.73M | 1.96% | n/a | 1.10% |
Assertio Therapeutics Inc | ASRT | Drug Manufacturers-Specialty & Generic | 1.35 | 128.70M | 3.85% | n/a | 30.76% |
Aceto Corporation | ACET | Drug Manufacturers-Specialty & Generic | 1.52 | 125.25M | 4.11% | n/a | 8.14% |
OptiNose Inc | OPTN | Drug Manufacturers-Specialty & Generic | 0.7956 | 119.96M | -6.40% | n/a | -294.40% |
Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 0.8012 | 117.28M | 4.05% | n/a | 36.36% |
Relmada Therapeutics Inc | RLMD | Drug Manufacturers-Specialty & Generic | 3.5 | 105.61M | 0.29% | n/a | 0.00% |
Karyopharm Therapeutics Inc | KPTI | Drug Manufacturers-Specialty & Generic | 0.7391 | 92.15M | 0.35% | n/a | -148.05% |
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 8.625 | 86.99M | 3.17% | n/a | 3.08% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Unifi Inc | UFI | Textile Manufacturing | 7.59 | 138.98M | 6.60% | n/a | 52.56% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 37.9 | 107.64M | -1.76% | 5.90 | 15.58% |
Culp Inc | CULP | Textile Manufacturing | 6.35 | 79.31M | 5.31% | n/a | 11.29% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 5.78 | 62.58M | -6.47% | n/a | 54.96% |
ILAG | ILAG | Building Products & Equipment | 1.04 | 18.78M | 13.06% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.02 | 12.43M | -7.27% | n/a | 16.03% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.737 | 11.34M | 3.80% | n/a | 422.08% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6475 | 6.16M | -2.76% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.315 | 4.97M | -1.56% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.42 | 3.63M | 1.43% | n/a | 9.62% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -4.04 | 16.67 | Cheaper |
Ent. to Revenue | - | 309.37 | - |
PE Ratio | - | 29.14 | - |
Price to Book | 207.70 | 12.81 | Expensive |
Dividend Yield | - | 2.80 | - |
Std. Deviation (3M) | 70.95 | 75.12 | Par |
Debt to Equity | -1.14 | -0.93 | Cheaper |
Debt to Assets | 3.38 | 0.45 | Expensive |
Market Cap | 176.87M | 5.22B | Emerging |